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P rostate cancer, the most frequent typeof cancer in men, is surpassed only bylung cancer in causing cancer-related
death. Despite major progress in defining
the mutational landscape of this tumor, its
etiology remains obscure. The intronic long-
noncoding RNA (lncRNA) PCA3 is a specific
marker of prostate cancer that acts as a
trans-dominant negative oncogene to down-
regulate the tumor suppressor gene PRUNE2.
The unusual genomic organization and
sequence of PCA3 leads us to hypothesize
that it was introduced into the human
genome by an as-yet undefined oncogenic
virus. We further suggest viral infection-
related mechanisms as functional in PCA3
overexpression and involved in prostate
cancer initiation and/or progression. This is
supported by known links between viral
infections and prostate cancer, and the lack
of this tumor in other mammals despite its
high incidence in humans. Finally, we
suggest that genomic sequence-based
approaches might help us uncover the
potential role of viruses in prostate cancer
etiology.
Introduction: The curious case of PCA3
in prostate cancer
The intronic lncRNA Prostate Cancer Antigen
3 (PCA3) is a highly specific biomarker:
While only present at low levels in normal or
benign hyperplastic prostate, its expression
is increased up to 100-fold in about 95% of
prostatic carcinomas (Schalken et al, 2003).
Despite this strong correlation, the biological
function of PCA3 remained elusive for almost
two decades after its discovery (Bussemakers
et al, 1999), until we established its role as a
trans-dominant negative oncogene that
downregulates a protein-coding tumor
suppressor gene, prune homolog 2 (PRUNE2)
(Salameh et al, 2015). In experimental
models of human prostate cancer, PCA3
overexpression as well as PRUNE2 silencing
accelerates the growth of tumor xenografts
in vivo, while increasing cell proliferation,
adhesion, and migration in vitro (Salameh
et al, 2015). In prostate cancer patients,
decreased levels of PRUNE2 are indicative of
poor prognosis, as this is associated with
metastatic disease (National Center for
Biotechnology Information, Gene Expression
Omnibus, NCBI GEO, profile 34856174;
n = 171) and a high Gleason score (The
Cancer Genome Atlas, TCGA; n = 497).
Surprisingly, data retrieved from large-scale
databases of human tissue samples (TCGA;
and The Atlas of noncoding RNAs in Cancer,
TANRIC) show homogeneous expression of
PCA3 only in prostate cancer, but not in
other tumor types, including those in which
PRUNE2 loss-of-function events have been
reported, that is, Merkel cell carcinoma,
neuroblastoma, glioblastoma, and parathy-
roid carcinoma.
From an evolutionary standpoint, PCA3
is a relatively new gene: All four exons and
the upstream (putative promoter-containing)
sequence are conserved among primates,
but only exon 4 shares conservation with
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the rabbit (68% identity) and mouse (52%
identity) orthologs. Prostate cancer occur-
rence is even more stringent than PCA3
conservation: Despite its high incidence in
humans, it is rare or absent in other
mammals (De Marzo et al, 1999), including
nonhuman primates kept in captivity (ruling
out the possibility that a shorter lifespan
might account for the difference). Dogs are
the only known exception, but even here the
incidence is much lower than in humans.
Moreover, while the vast majority of pros-
tate cancers in men are androgen-dependent
adenocarcinomas, dogs more often present
with androgen-independent ductal carcino-
mas. A simple link between human diet and
predisposition to prostate cancer (De Marzo
et al, 1999) also does not satisfactorily
explain the paradoxical (non)-diffusion of
this tumor. The intriguing association
between PCA3 and prostatic carcinoma in
human males is at odds with the established
concept that oncogenes are shared among
different tumor types and/or animal species.
How might this tissue- and species-specifi-
city be linked to the currently unknown trig-
gering event(s) in prostate cancer?
A connection between oncoviruses,
long noncoding RNAs, and cancer:
coevolution to optimize fitness
Tumor-related lncRNA transcripts are often
encoded and/or regulated by viruses.
Indeed, all known oncoviruses, including
hepatitis B and C viruses (HBV and HCV,
respectively), Epstein–Barr virus (EBV),
human papillomavirus (HPV), and Kaposi’s
sarcoma-associated herpesvirus (KSHV),
produce their own lncRNAs and/or induce
the transcription of cellular lncRNAs,
contributing to cancer predisposition (Li
et al, 2016). This “virus-lncRNA-cancer”
leitmotif has been validated in different
malignant settings including HBV-Highly
Upregulated in Liver Cancer (HULC) in hepa-
tocellular carcinoma, EBV-Small Nucleolar
RNA Host Gene 8 (SNHG8) in gastric cancer,
and HPV-HOX transcript antisense intergenic
RNA (HOTAIR) in cervical cancer. The
connection is not limited to ongoing infec-
tions: Ancient viruses and their animal hosts
have actively exchanged portions of genetic
material throughout evolution (Krupovic &
Koonin, 2017). This phenomenon is related
to the need of viruses to optimize their
replication by exploiting the eukaryotic
cell machinery. In addition, random viral
insertions can lead to the formation of virus-
host chimeric functional units (e.g.,
lncRNAs) that are selected for their capacity
to favor host functions in physiological and/
or pathological conditions (e.g., cancer,
inflammation, immunity). A consequence of
this coevolution, the conservation between
viral sequences and lncRNAs in at least
mammals and birds, is beginning to be
unraveled with regard to genomic structure
and regulation. An interesting example in the
poultry industry is the integration of several
related avian leukosis viruses with miRNAs
and lncRNAs to cause tumors, decreased
fertility, and premature death (Lan et al,
2017).
Is PCA3 an oncovirus-derived gene?
Several attributes of PCA3 suggest that this
lncRNA may be derived from and/or regu-
lated by viruses. First, the PCA3 promoter
and exon 1 are included in a partially
conserved long interspersed nuclear element
type 2 (LINE-2) repeat, which is an ancient
virus-derived retrotransposon. This is simi-
lar to the HBV-regulated lncRNA HULC,
whose promoter and first exon are embed-
ded in a long-terminal repeat (LTR) retro-
transposon-like sequence (Kapusta et al,
2013). Second, as would be expected if the
PCA3 promoter were derived from a virus, it
does not contain canonical transcription
factor binding sites (e.g., TATA box) and
shows no sequence conservation with any
annotated human promoter. Third, PCA3 is
located on the opposite DNA strand to intron
6 of the PRUNE2 gene. This configuration is
reminiscent of the bidirectional transcription
of the EBV latency origin of replication, with
leftward transcripts being mainly noncoding
and regulatory, and rightward transcripts
containing open reading frames (Cao et al,
2015). Fourth, PRUNE2 downregulation by
PCA3 occurs through adenosine deaminase
acting on RNA (ADAR)-mediated editing, a
post-transcriptional mechanism largely
employed in the cellular response to viruses
such as polyomavirus and EBV (Cao et al,
2015), and upregulated in EBV-infected
lymphocytes (http://www.gtexportal.org/
home/gene/ADAR).
A tale of sex, viral transmission, and
human prostate cancer
Human prostate cancer has been associated
with several viruses. Digital expression
studies have shown that the human
endogenous retrovirus K (HERV-H), a
remnant of ancient infections fixed in the
ancestral human genome 30–70 millions of
years ago, is overexpressed in human
stomach, colon and prostate cancers. The
activation of an analogous retrovirus,
HERV-K, induces the production of corre-
sponding antigens and immune responses
(Reis et al, 2013) that correlate with pros-
tate cancer progression. A few additional
indications of a direct viral etiology also
exist. The BK polyomavirus (BKV) seems
to be a cofactor in early stages of prostate
cancer (Das et al, 2008), and its correlation
with malignant progression has been
proposed. Overall, a 19% prevalence of
polyomaviruses such as BKV, JC virus
(JCV), and SV40 has been reported in pros-
tate cancer cases, suggesting that the
subclinical persistent infections that are
frequent in the human population might
contribute to the onset and/or progression
of this malignancy. Positive association
with other oncoviruses such as HPV has
also been established. In general, an
increased relative risk estimate for prostate
cancer has been associated with sexually
transmitted diseases (e.g., gonorrhea and
syphilis) (Dennis & Dawson, 2002),
supporting the possibility of infectious
components in tumor development. Despite
their limitations, these data are encourag-
ing: The challenge of finding a direct link
between viral infection and cancer is
common to a number of pathologies for
which standard causation rules, for exam-
ple, Koch’s postulates and Hill’s criteria of
causality (reviewed in Moore & Chang,
2014), do not apply. Heterogeneous etiolo-
gies have been described for other virus-
linked cancers, for example, Merkel cell
carcinoma, where the presence of poly-
omavirus alone is not sufficient for tumor
development as well as squamous cell
carcinomas of the genital and head-and-
neck regions, in which HPV infection
appears to be a necessary yet insufficient
cause (zur Hausen, 2002).
Conclusion: How could this hypothesis
be tested?
To actually demonstrate the connection
between viral infection, lncRNAs, and
prostate cancer, the characterization of
the variety of viruses present in tumor
cells will be needed. Digital transcript
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subtraction has been successfully applied
to uncover the association between poly-
omavirus and human Merkel cell carci-
noma (Feng et al, 2008) and could also be
employed to hunt for new oncoviruses in
prostate cancer. To cover the full spectrum
of virus-related mechanisms, a properly
designed variant of this in silico strategy
should be designed to include noncoding
RNAs. Such next-generation approaches
would rule out potential contaminations,
as in the unfortunate precedent of xeno-
tropic murine leukemia-related virus
(XMRV), a putative retrovirus involved in
prostate cancer later demonstrated to be a
laboratory artifact (Paprotka et al, 2011).
Also, a systematic analysis of virus-derived
genomic sequences in a large cohort of
prostate cancer patients would elucidate
the structural connections between
lncRNAs and ancient infections, as a
preliminary step toward a comprehensive
functional characterization of the corre-
sponding mechanisms. Above all, this anal-
ysis should allow low stringency homology
searches, to include poorly conserved
sequences (such as the LINE-2 repeat in
which PCA3 is embedded) derived from
millions of years of evolutionary pressure,
and thereby barely recognizable.
In summary, we hypothesize that the
prostate-specific lncRNA PCA3 has been
introduced into the human genome by an
ancient virus, and that it is regulated by
virus-specific mechanisms (Fig 1). The iden-
tification of cellular and/or viral regulatory
processes that are specifically engaged in
prostate pathophysiology will be pivotal for
understanding the contribution of PCA3 and
other noncoding RNA transcripts in the
onset and progression of prostate cancer, as
well as the peculiar restriction of this tumor
to humans.
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Figure 1. Schematic view of the proposed viral etiology of prostate cancer.
In the normal prostate, basal expression of PRUNE2 correlates with low PCA3 levels. In prostate cancer, a putative oncovirus could activate PCA3 expression through a direct
transactivation of a cryptic, ancient virus-derived promoter, resulting in downmodulation of PRUNE2, and leading to dysregulated cell proliferation and acquisition of
malignant attributes.
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